Cargando…

PCSK9 Inhibitors in the Management of Cardiovascular Risk: A Practical Guidance

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors are potent medications in the toolkit for treatment of atherosclerotic cardiovascular disease. These agents have been well studied in clinical trials supporting their efficacy in dramatically reducing low-density lipoprotein cholestero...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jia, Xiaoming, Al Rifai, Mahmoud, Saeed, Anum, Ballantyne, Christie M, Virani, Salim S
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309324/ https://www.ncbi.nlm.nih.gov/pubmed/35898405 http://dx.doi.org/10.2147/VHRM.S275739

Ejemplares similares

Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
por: Jia, Xiaoming, et al.
Publicado: (2020)

PCSK9 inhibitors in the prevention of cardiovascular disease
por: Latimer, James, et al.
Publicado: (2016)

Highlights of Studies in Cardiovascular Disease Prevention Presented at the 2020 American College of Cardiology Annual Scientific Session
por: Jia, Xiaoming, et al.
Publicado: (2020)

Highlights from Studies in Cardiovascular Disease Prevention Presented at the Digital 2020 European Society of Cardiology Congress: Prevention Is Alive and Well
por: Jia, Xiaoming, et al.
Publicado: (2020)

Identifying Differences: A Key Step in Precision Cardiovascular Disease Prevention
por: Al Rifai, Mahmoud, et al.
Publicado: (2022)

Evaluation of Aspirin and Statin Therapy Use and Adherence in Patients With Premature Atherosclerotic Cardiovascular Disease
por: Mahtta, Dhruv, et al.
Publicado: (2020)

E-cigarette Use and Risk Behaviors among Lesbian, Gay, Bisexual, and Transgender Adults: The Behavioral Risk Factor Surveillance System (BRFSS) Survey
por: Al Rifai, Mahmoud, et al.
Publicado: (2020)

Effect of Access to Prescribed PCSK9 Inhibitors on Cardiovascular Outcomes
por: Myers, Kelly D., et al.
Publicado: (2019)

Racial and geographic disparities in influenza vaccination in the U.S. among individuals with atherosclerotic cardiovascular disease: Renewed importance in the setting of COVID-19
por: Al Rifai, Mahmoud, et al.
Publicado: (2021)

Acute Tubular Injury in a Patient on a Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor
por: Pickett, June K., et al.
Publicado: (2020)

FOURIER & PCSK9 RNAi: Towards enhancing durability and efficacy of PCSK9 inhibitors
por: Hassan, Mohamed
Publicado: (2017)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

Pleiotropic Effects of PCSK-9 Inhibitors
por: Basiak, Marcin, et al.
Publicado: (2021)

PCSK9 Inhibitors in Lipid Management of Patients With Diabetes Mellitus and High Cardiovascular Risk: A Review
por: Handelsman, Yehuda, et al.
Publicado: (2018)

Potential dual inhibitors of PCSK-9 and HMG-R from natural sources in cardiovascular risk management
por: Waiz, Mohd, et al.
Publicado: (2022)

PCSK9 inhibitors and cardiovascular disease: heralding a new therapeutic era
por: Chapman, M. John, et al.
Publicado: (2015)

Indications of PCSK9 Inhibitors for Patients at High and Very High Cardiovascular Risk
por: Behr, Paulo Eduardo Ballvé, et al.
Publicado: (2018)

Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
por: Pećin, Ivan, et al.
Publicado: (2017)

PCSK-9 Inhibitors and Cardiovascular Outcomes: A Systematic Review With Meta-Analysis
por: Bodapati, Adi prasad, et al.
Publicado: (2023)

Effectiveness and safety of PCSK9 inhibitors in real-world clinical practice. An observational multicentre study. The IRIS-PCSK9I study
por: Blanco-Ruiz, Marina, et al.
Publicado: (2021)

PCSK9 Inhibitors for the Management of Mitotane-Induced Hypercholesterolemia in Adrenocortical Carcinoma
por: Aurora, John A, et al.
Publicado: (2021)

Eligibility, Clinical Outcomes, and Budget Impact of PCSK9 Inhibitor Adoption: The CANHEART PCSK9 Study
por: Ko, Dennis T., et al.
Publicado: (2018)

The Anti-Thrombotic Effects of PCSK9 Inhibitors
por: Péč, Martin Jozef, et al.
Publicado: (2023)

Racial/Ethnic Disparities and Determinants of Sufficient Physical Activity Levels
por: Patel, Nikhil Anil, et al.
Publicado: (2022)

PCSK9 Inhibitors: Clinical Relevance, Molecular Mechanisms, and Safety in Clinical Practice
por: Ferrari, Filipe, et al.
Publicado: (2019)

Racial and Geographic Disparities in Internet Use in the U.S. Among Patients With Hypertension or Diabetes: Implications for Telehealth in the Era of COVID-19
por: Jain, Vardhmaan, et al.
Publicado: (2021)

PCSK9 as a therapeutic target for cardiovascular disease
por: Zhang, Pei-Ying
Publicado: (2017)

OSLER and ODYSSEY LONG TERM: PCSK9 inhibitors on the right track of reducing cardiovascular events
por: Hassan, Mohamed
Publicado: (2015)

Application Value of PCSK9 Inhibitor in Cardiovascular High Risk Patients: A Meta-Analysis
por: Zhao, Liming, et al.
Publicado: (2023)

PCSK9 Inhibitors Reduce PCSK9 and Early Atherogenic Biomarkers in Stimulated Human Coronary Artery Endothelial Cells
por: Zulkapli, Rahayu, et al.
Publicado: (2023)

Mental Health and Access to Medical Care in Patients with Chronic Cardiovascular Conditions: An Analysis of the Behavior Risk Factor Surveillance System
por: Kherallah, Riyad Y., et al.
Publicado: (2022)

Statement for Appropriate Clinical Use of PCSK9 Inhibitors
por: Nohara, Atsushi, et al.
Publicado: (2018)

Just Price for PCSK9 Inhibitors: No less, No More
por: Nasir, Khurram
Publicado: (2018)

Safety and Tolerability of PCSK9 Inhibitors: Current Insights
por: Kosmas, Constantine E, et al.
Publicado: (2020)

Finding inhibitors for PCSK9 using computational methods
por: Zainab, Rida, et al.
Publicado: (2021)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Physiological and therapeutic regulation of PCSK9 activity in cardiovascular disease
por: Glerup, Simon, et al.
Publicado: (2017)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

Monoclonal Antibodies in the Management of Familial Hypercholesterolemia: Focus on PCSK9 and ANGPTL3 Inhibitors
por: Pirillo, Angela, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6u0e2ap8juopqo2i1nklp9cr8t